APP and early-onset autosomal dominant Alzheimer disease: In the present study, we evaluated the efficacy of DNLAs extract DDB on improving cognitive function, neuronal and synaptic efficacy, and the degradation of APP/tau products in the triple-transgenic mouse model of Alzheimer’s disease (3 × Tg-AD), which expresses mutant human APP, presenilin, and tau proteins.